Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02027883
Other study ID # VF Induction
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 2011
Est. completion date August 2012

Study information

Verified date April 2018
Source Wellmont CVA Heart Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

As the indications for Implantable Cardioverter Defibrillator implantation expand, minimizing implant time is critical. Also, patients receiving biventricular ICDs are sometimes more unstable and minimization of sedation time is crucial. Multiple induction attempts, with a 1-Joule shock, can cause disruption in lead position. Therefore limiting the number of attempts will allow for better lead stability throughout the procedure and a more straightforward implant process.

Investigator proposes a detailed documentation of success rates from various Ventriculart Fibrillation induction methods during implant of Medtronic defibrillation capable devices.


Description:

Our clinical experience has found that attempts to induce patients receiving ICDs at implant using the nominal Medtronic T-shock settings are not always effective at inducing ventricular fibrillation. When this results, a change to the parameters for T-shock is made before reattempting to induce ventricular fibrillation in patients undergoing ICD implantation.

Another available induction method is 50 Hz Burst. "The 50 Hz Burst induction is designed to induce VF by delivering a rapid burst of pacing pulses. The amplitude and pulse width of these pulses are selectable, but the pacing interval is fixed at 20 ms."2 If multiple attempts using the T-shock method are unsuccessful, 50 Hz Burst provides an additional method for inducing ventricular fibrillation. It is a less desirable method since it can result in very fine VF that is difficult to identify the initiation of possibly resulting in longer times in VF causing higher defibrillation threshold or in undersensing due to the fine nature of the rhythm.

T-shock has been found to be a fast and reliable method for inducing ventricular fibrillation in ICD implants. Greater success of inducing ventricular fibrillation using the T-shock method has been found when the energy of the T-shock was higher and the coupling interval was shorter. In addition, increasing the shock strength increases the window of vulnerability. For the T-shock method to be most efficient, initial success at inducing ventricular fibrillation, and therefore a reduced number of attempts, is important. This requires a better understanding of the optimal programmed settings for the initial T-shock induction attempt.

Moreover, in recent years, ICD indications have grown to include primary prevention patients. These patients may have different vulnerable periods than patients previously evaluated to develop Medtronic nominal settings.

Our clinical experience has found that the nominal T-shock settings are only effective at inducing ventricular fibrillation approximately seventy-five percent of the time. However, a detailed collection of success rates has not been performed.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- All patients undergoing Medtronic ICD or Cardiac Resynchronization Therapy-Defibrillator implant (initial implant or generator replacement) will be included.

Exclusion Criteria:

- Any patient who is medically unstable and testing is deemed unsafe by physician will be excluded from this study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Nominal T shock setting
Nominal Parameter Set 1 Programming Values for EnTrust
Educated T shock setting
Experimental Parameter Set 2 Programming Values

Locations

Country Name City State
United States Wellmont CVA Heart Institute Kingsport Tennessee

Sponsors (2)

Lead Sponsor Collaborator
James Merrill Medtronic

Country where clinical trial is conducted

United States, 

References & Publications (5)

Bardy G, Mehra R, Johnson G, Kudenchuk P, Dolack G, Poole J, Hofer B: Low energy pulsing on the T-wave: A new programming method for intentional, device mediated induction of ventricular fibrillation for defibrillation testing. PACE 15(4, Pt II): 562, 1992.

Bhandari AK, Isber N, Estioko M, Ziccardi T, Cannom DS, Park Y, Lerman RD, Prejean C, Sun GW. Efficacy of low-energy T wave shocks for induction of ventricular fibrillation in patients with implantable cardioverter defibrillators. J Electrocardiol. 1998 Jan;31(1):31-7. — View Citation

Marquis DR Reference Manual, Medtronic, Inc.

Mitchell L, Yee R, Talajic M, Newman D, Sheldon R, Kerr C, Kus T, Boyle A, Canadian Jewel PCD Investigators: Low-energy, T-wave synchronous, interval shock for rapid, reliable ventricular fibrillation induction by an implantable cardioverter defibrllattor. PACE, 17(4, Pt II): 851, 1994.

Swartz J, Stanton M, DeGroot P, Mehra R: Influence of T-wave shock energy on ventricular fibrillation vulnerability in humans. JACC 1995 Conference Abstracts: 214A, 1995.

Outcome

Type Measure Description Time frame Safety issue
Other Safety Monitoring Number of participants that were monitored for safety issues, including increased heart rate, blood pressure, decreased oximetry levels, and stable rhythm during the entire procedure. 2 hours
Primary Sustained Ventricular Fibrillation The primary endpoint is the successful induction of sustained ventricular fibrillation. 2 hours
Secondary Factors Determine if any pre-implant patient demographics are factors impacting T-shock success according to parameter settings. 2 hours
See also
  Status Clinical Trial Phase
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2
Completed NCT02892448 - Cardiac MRI for Metal on Metal Hip Resurfacing N/A
Active, not recruiting NCT02537782 - Myocardial Work and Metabolism in CRT N/A
Completed NCT02525185 - Contractile Reserve in Dyssynchrony: A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy
Terminated NCT01705509 - The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC) N/A
Completed NCT00999947 - Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy N/A
Completed NCT00626028 - Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing Phase 3
Recruiting NCT00138931 - Genetics of Cardiovascular and Neuromuscular Disease
Withdrawn NCT02838355 - Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients N/A
Completed NCT01085955 - Investigation in Pregnancy Associate Cardiomyopathy N/A
Withdrawn NCT00428103 - Effects of Mitral Valve Repair With the Geoform Ring on Cardiomyopathy N/A
Recruiting NCT00273637 - Registry and Survey of Women With Pregnancy Related Cardiomyopathy N/A
Completed NCT00810550 - Carotid Ultrasound in the Evaluation of Heart Failure N/A
Completed NCT04603521 - Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)
Enrolling by invitation NCT03057561 - Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance N/A
Completed NCT00027170 - Technical Development of Cardiovascular Magnetic Resonance Imaging
Not yet recruiting NCT02917395 - Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients N/A
Completed NCT02164721 - Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy N/A
Completed NCT02331264 - Cardiac Assessment of Patients With Hip Implants N/A
Completed NCT02270840 - Budapest Upgrade CRT Study (Version 009-4.1) N/A